Swiss drugmaker Roche beat third-quarter sales ​expectations on Thursday, supported by steady demand for key medicines such ‌as Ocrevus to buy time as it looks abroad to restock a pipeline facing looming patent expiries.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in